Nanterinone

南力农

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameNanterinone
Drug Alias Namenanterinone mesylateUK-61260UK-61260-27
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 3 inhibitors
TargetsPhosphodiesterase 3
Therapy Area/IndicationsHeart Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsHeart Failure

Other Information

ATC CodeN/A
Related LinksN/A